CVAC Logo

CureVac NV (CVAC) Stock Forecast & Price Prediction

Live CVAC Stock Price & Analysis

Home โ€บ Stocks โ€บ Germany | NASDAQ | Healthcare | Biotechnology

$3.58

-0.15 (-4.02%)

12 Month Price Forecast For CVAC

$3.58
Current Price
$805.37M
Market Cap
7 Ratings
Buy 4
Hold 2
Sell 1
Wall St Analyst Ratings

Distance to CVAC Price Forecasts

+336.6%
To High Target of $15.63
+37.1%
To Median Target of $4.91
-31.9%
To Low Target of $2.44

CVAC Price Momentum

-5.5%
1 Week Change
-15.4%
1 Month Change
+2.9%
1 Year Change
+5.0%
Year-to-Date Change
-32.2%
From 52W High of $5.28
+61.6%
From 52W Low of $2.22

๐Ÿค” Considering CureVac (CVAC)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 9:57 AM UTC

CVAC Analyst Ratings & Price Targets

Based on our analysis of 7 Wall Street analysts, CVAC has a consensus that is bullish. The median price target is $4.91, with forecasts ranging from $2.44 to $15.63. Currently, there are 4 Buy ratings, 2 Hold ratings, and 1 Sell ratings.

With CVAC currently trading at $3.58, the median price forecast suggests a 37.1% upside. The most optimistic forecast comes from at , projecting a 336.6% upside, while at provides the most conservative target, suggesting a -31.9% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CVAC Analyst Consensus

4
Buy
2
Hold
1
Sell

CVAC Price Target Range

Low
$2.44
Average
$4.91
High
$15.63
Current: $3.58

Latest CVAC Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CVAC.

Date Firm Analyst Rating Change Price Target
Sep 16, 2024 JMP Securities Roy Buchanan Market Outperform Reiterates $16.00
Aug 16, 2024 JMP Securities Roy Buchanan Market Outperform Maintains $16.00
Jul 3, 2024 JMP Securities Roy Buchanan Market Outperform Reiterates $18.00
Apr 25, 2024 Leerink Partners Mani Foroohar Market Perform Downgrade $4.00
Apr 5, 2024 Guggenheim Evan Wang Neutral Reiterates $0.00
Aug 21, 2023 B of A Securities Geoff Meacham Underperform Maintains $8.00
Jun 8, 2023 SVB Securities Mani Foroohar Outperform Initiates $13.00
Apr 26, 2023 JMP Securities Roy Buchanan Outperform Maintains $24.00
Jan 19, 2023 UBS Eliana Merle Buy Upgrade $18.00
Jan 9, 2023 Jefferies Eun Yang Buy Upgrade $0.00
Nov 17, 2022 JMP Securities Roy Buchanan Market Outperform Maintains $34.00
Apr 22, 2022 JMP Securities Roy Buchanan Market Outperform Maintains $37.00
Jan 21, 2022 B of A Securities Geoff Meacham Underperform Downgrade $20.00
Dec 31, 2021 Deutsche Bank Hold Initiates $0.00
Oct 22, 2021 Deutsche Bank Hold Initiates $0.00
Jun 17, 2021 B of A Securities Neutral Downgrade $0.00
Apr 26, 2021 Guggenheim Buy Initiates $0.00
Dec 10, 2020 Credit Suisse Underperform Downgrade $0.00
Sep 8, 2020 B of A Securities Buy Initiates $0.00
Sep 8, 2020 Jefferies Hold Initiates $0.00

Stocks Similar to CureVac NV

The following stocks are similar to CureVac based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

CureVac NV (CVAC) Financial Data

CureVac NV has a market capitalization of $805.37M with a P/E ratio of 7.3x. The company generates $68.00M in trailing twelve-month revenue with a -131.3% profit margin.

Revenue growth is +90.5% quarter-over-quarter, while maintaining an operating margin of -493.6% and return on equity of -54.3%.

Valuation Metrics

Market Cap $805.37M
Enterprise Value $695.09M
P/E Ratio 7.3x
PEG Ratio -8.2x
Price/Sales 12.2x

Growth & Margins

Revenue Growth (YoY) +90.5%
Gross Margin +95.6%
Operating Margin -493.6%
Net Margin -131.3%
EPS Growth +2,896.4%

Financial Health

Cash/Price Ratio +25.2%
Current Ratio 2.3x
Debt/Equity 10.4x
ROE -54.3%
ROA -24.5%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

CureVac NV logo

CureVac NV (CVAC) Company Overview

About CureVac NV

What They Do

Develops transformative mRNA-based medicines.

Business Model

CureVac N.V. focuses on developing innovative mRNA-based therapies and vaccines. The company generates revenue through the advancement of its drug candidates into clinical trials, aiming for eventual commercialization and partnerships with other pharmaceutical companies.

Additional Information

Founded in 2000 and headquartered in Tรผbingen, Germany, CureVac is actively working on several vaccine candidates targeting diseases like COVID-19 and rabies, as well as cancer treatments. The company's work in mRNA technology positions it strategically within the biopharmaceutical industry, which is seeing increased interest and investment in mRNA therapies.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

999

CEO

Dr. Alexander Zehnder M.B.A., M.D.

Country

Germany

IPO Year

2020

CureVac NV (CVAC) Latest News & Analysis

CVAC stock latest news image
Quick Summary

CureVac's CVGBM vaccine showed positive safety and immunogenicity in phase 1 for glioblastoma. Key milestones include data in 2025 and a phase 2 study in 2026. They are also advancing a vaccine for NSCLC.

Why It Matters

CureVac's positive vaccine data and upcoming key study milestones could enhance its market position and attractiveness, potentially boosting stock value and investor interest.

Source: Seeking Alpha
Market Sentiment: Positive
CVAC stock latest news image
Quick Summary

Small-cap stocks tend to perform well in bullish markets due to their growth potential and sensitivity to improving economic conditions, attracting investor confidence and capital.

Why It Matters

Small-cap stocks may lead market gains in bullish conditions, attracting risk-seeking investors, which can boost overall market performance and influence portfolio allocations.

Source: MarketBeat
Market Sentiment: Positive
CVAC stock latest news image
Quick Summary

CureVac (CVAC) stock is experiencing notable activity in the options market, signaling that investors should monitor it closely.

Why It Matters

Increased activity in CureVac's options market signals potential volatility or significant price movement, which could impact stock performance and investment strategies.

Source: Zacks Investment Research
Market Sentiment: Neutral
CVAC stock latest news image
Quick Summary

CureVac N.V. will hold its Q3 2024 earnings conference call on November 12, 2024, at 9:00 AM ET, featuring key executives and analysts from major financial institutions.

Why It Matters

CureVac's Q3 earnings call will provide crucial insights into its financial performance and strategic direction, impacting stock valuation and investor sentiment.

Source: Seeking Alpha
Market Sentiment: Neutral
CVAC stock latest news image
Quick Summary

CureVac reported a โ‚ฌ400M upfront payment from GSK, raising cash to โ‚ฌ551M, extending runway to 2028. Positive trial results in glioblastoma and influenza, new cancer program initiated, and workforce cut planned.

Why It Matters

The substantial cash increase and pipeline advancements signal strong financial health, operational efficiency, and growth potential, positively influencing investor confidence and stock performance.

Source: Accesswire
Market Sentiment: Neutral
CVAC stock latest news image
Quick Summary

CureVac N.V. will release its Q3 and 2024 year-to-date financial results and business updates on November 12, 2024.

Why It Matters

CureVac's upcoming financial report may impact its stock performance, providing insights into its mRNA developments and overall market position, influencing investor sentiment and decisions.

Source: Accesswire
Market Sentiment: Neutral

Frequently Asked Questions About CVAC Stock

What is CureVac NV's (CVAC) stock forecast for 2025?

Based on our analysis of 7 Wall Street analysts, CureVac NV (CVAC) has a median price target of $4.91. The highest price target is $15.63 and the lowest is $2.44.

Is CVAC stock a good investment in 2025?

According to current analyst ratings, CVAC has 4 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $3.58. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CVAC stock?

Wall Street analysts predict CVAC stock could reach $4.91 in the next 12 months. This represents a 37.1% increase from the current price of $3.58. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is CureVac NV's business model?

CureVac N.V. focuses on developing innovative mRNA-based therapies and vaccines. The company generates revenue through the advancement of its drug candidates into clinical trials, aiming for eventual commercialization and partnerships with other pharmaceutical companies.

What is the highest forecasted price for CVAC CureVac NV?

The highest price target for CVAC is $15.63 from at , which represents a 336.6% increase from the current price of $3.58.

What is the lowest forecasted price for CVAC CureVac NV?

The lowest price target for CVAC is $2.44 from at , which represents a -31.9% decrease from the current price of $3.58.

What is the overall CVAC consensus from analysts for CureVac NV?

The overall analyst consensus for CVAC is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $4.91.

How accurate are CVAC stock price projections?

Stock price projections, including those for CureVac NV, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.